Gastric cancer (GC), the fifth most common malignancy globally, poses significant therapeutic challenges and remains the third leading cause of cancer-related mortality. Despite advancements in medical science, the conventional duo of surgery and chemotherapy has been largely insufficient in improving outcomes for patients, especially in the metastatic arena. Existing within this dire landscape, the emergence of immunotherapy, particularly with the advent of avelumab, a human IgG1 antibody targeting PD-L1, heralds a potential paradigm shift in GC management. This elaboration delves into the chemistry, pharmacology, and clinical efficacy of avelumab for GC treatment based on the synthesis of clinical trial data, giving hope to those engaged in the grim battle against this relentless disease.
Keywords
1. Avelumab gastric cancer
2. Immunotherapy for GC
3. Gastric cancer treatment
4. PD-L1 inhibitors
5. Avelumab clinical trials
Introduction
Gastric cancer, a formidable adversary in the oncology discipline, claims an enormous toll on human life with its aggressive course and limited successful treatment strategies. It is within the past decade that the landscape of cancer treatment has been reshaped by the inception of immunotherapy, a modality that revolutionizes the approach towards many cancer types, including gastric cancer. Avelumab, in particular, has emerged as a beacon of hope for this virulent disease. This article reviews the properties and clinical progress of avelumab, a drug that has already shown promise in treating Merkel cell carcinoma and urothelial carcinoma, in the context of gastric cancer.
Chemical Structure and Pharmacologic Properties
Avelumab (MSB0010718C) is an IgG1 monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1), which is expressed on the surface of cancer cells and tumor-infiltrating immune cells. By blocking the interaction of PD-L1 with its receptors PD-1 and B7.1, avelumab lifts the inhibition of immune responses, thus facilitating the reactivation of T cells to target tumor cells. Its chemical structure is unique in that it possesses a mutated Fc region that reduces antibody-dependent cell-mediated cytotoxicity, skewing its mechanism of action towards immune checkpoint inhibition.
Clinical Efficacy of Avelumab in Gastric Cancer
The journey of avelumab from the laboratory to clinical use in gastric cancer patients is a testament to the strides made in personalized and targeted medicine. The drug’s efficacy was first hinted at in preclinical studies, which led to the ushering in of clinical trials tailored to evaluate its potency in the gastric cancer setting.
The preliminary data from these trials suggest that avelumab holds substantial promise in the treatment of advanced GC, particularly for those who have previously undergone chemotherapy regimes without success. Phase I trials have demonstrated its safety and tolerability, with manageable side effects compared to traditional chemotherapy. Subsequent phase II and III trials have focused more on therapeutic outcomes such as progression-free survival (PFS) and overall survival (OS), comparing avelumab both as a single agent and in combination with other treatments. Notably, the findings from these trials underscore avelumab’s potential in improving clinical outcomes for patients with advanced GC.
Avelumab’s Role In Ongoing Clinical Studies
Building on the momentum of encouraging trial results, ongoing studies are further exploring avelumab’s application as a single agent and in synergistic combinations. These include combinations with chemotherapy, radiation therapy, and other immunomodulatory drugs, which are designed to enhance the anti-tumor immune response. There is a particular interest in understanding how avelumab can be integrated into treatment plans that might be tailored according to a patient’s specific tumor characteristics, such as PD-L1 expression levels.
Challenges and Future Directions
Despite the promising findings, the application of avelumab in gastric cancer is not without its challenges. Drug resistance, variable PD-L1 expression, and the heterogeneous nature of gastric cancer are just a few of the issues that influence the efficacy of avelumab. Furthermore, identifying the subset of patients most likely to benefit from avelumab remains an ongoing endeavor. Future research is directed toward optimizing the use of biomarkers for patient selection, determining the most effective drug combinations, and understanding the long-term effects of treatment with avelumab.
Conclusion
Avelumab ushers in an era of immunotherapy for gastric cancer, presenting a glimmer of hope where the prognosis was once grim. As the clinical trials progress, and our understanding of the drug’s interaction with gastric cancer deepens, there is potential for establishing avelumab as a cornerstone in the treatment of this disease. With continued research and refining of clinical approaches, avelumab may soon redefine the standard care for patients struggling with gastric cancer, delivering a new lease on life for many.
References
1. Roviello G, D’Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, de Manzini N, Sobhani N. Avelumab in gastric cancer. Immunotherapy. 2019 Jun;11(9):759-768. doi: 10.2217/imt-2019-0011.
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
3. Couzin-Frankel J. Cancer immunotherapy. Science. 2013 Dec 20;342(6165):1432-1433. doi: 10.1126/science.342.6165.1432.
4. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park JS, Kollia GD, Hanks DA, Reilly EB, Korman AJ, Carvajal RD. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab. J Clin Oncol. 2013 Jul 10;31(22):2712-2718. doi: 10.1200/JCO.2012.47.1177.
5. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Minami H, Zhang Y, Ohtsu A, Tabernero J. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.